|
CN109312342A
|
|
Target nucleic acid conjugates composition
|
|
WO2016197132A1
|
|
Treating hepatitis b virus infection using crispr
|
|
WO2016183366A2
|
|
Compositions and methods for silencing expression of hepatitis d virus rna
|
|
CA2979998A1
|
|
Compositions and methods for treating hypertriglyceridemia
|
|
WO2016071857A1
|
|
Compositions and methods for silencing ebola virus expression
|
|
US2016076035A1
|
|
Compositions and methods for silencing marburg virus gene expression
|
|
WO2015011633A1
|
|
Compositions and methods for delivering messenger rna
|
|
US2014134260A1
|
|
Cationic lipids and methods for the delivery of therapeutic agents
|
|
US2014288146A1
|
|
Novel trialkyl cationic lipids and methods of use thereof
|
|
AU2013202932A1
|
|
Novel lipid formulations for nucleic acid delivery
|
|
AU2013202970A1
|
|
Silencing of polo-like kinase expression using interfering RNA
|
|
CN110003030A
|
|
Trialkyl cation lipid and its application method
|
|
US2013172405A1
|
|
Compositions and methods for silencing SMAD4
|
|
AU2012318249A1
|
|
Compositions and methods for silencing aldehyde dehydrogenase
|
|
AU2011253734A1
|
|
Cationic lipids and methods of use
|
|
WO2012000104A1
|
|
Non-liposomal systems for nucleic acid delivery
|
|
WO2011141704A1
|
|
Novel cyclic cationic lipids and methods of use
|
|
WO2011141703A1
|
|
Compositions and methods for silencing apolipoprotein b
|
|
US2013022649A1
|
|
Snalp formulations containing antioxidants
|
|
EP2480668A2
|
|
Compositions and methods for silencing genes expressed in cancer
|
